Table 3.
Population | KRI | IC | IDM | Other |
---|---|---|---|---|
Global | N = 6,826–8,072 M (2010–2029), R0 = 4–13 by WBIL [18, 20] N = 2,526–9,640 M (1950–2100), R0 = 4–13 by WBIL for WPV1, WPV1*0.9 for WPV2, WPV1*0.75 for WPV3 [4, 50–62, 65, 77, 81] |
|||
Country group* | ||||
|
N = 3,600 M in 1988, R0 = 7.5 (LI), 9.5 (LMI), 11.5 (UMI) [25] | |||
|
N = 2,933–3,992 M (2010–2029), R0 = 10 or 13 [19, 22] | |||
|
R0 = 1.2–3 for cVDPV2 [133] | |||
|
[164] | |||
|
N = 613 M (2013), R0 = V [157] | |||
GPEI polio-endemic countries (as of 2006) | ||||
|
N = 247 M (2006), R0 = 16 [19] N = 54–224 M (1950–2100), R0 = 13 [33] N = 55–224 M (1950–2100), R0 = 13 [35, 36, 46] |
[134] | ||
|
N = 9.7–186 M (northwest zone, 1950–2100), R0 = 8 [33] N = 9.7–234 M (northwest zone, 1950–2100), R0 = 7.5 [35, 40, 46, 49, 64] |
N = 0.01 M, R0 = 5 [100] | [133] N = 0.3 M [129] N = 1.8 M (Kano, 2016), R0 = V [132] |
|
|
N = 45–422 M (1950–2100), R0 = 11 [71, 73–76] | |||
Other countries modeled by at least one GPEI-supported modeling group | ||||
|
N = 1.3–15 M (1950–2100), R0 = 5–6 [43, 46, 47] | N = 0.050–0.067 M (2012–2014), R0 = 1–10 [162] N = 100%, R0 = 1.62 [166] |
||
|
N = 1.5–11 M (1950–2100), R0 = 7–8 [33] N = 1.5–21 M (1950–2100), R0 = 8 [35, 46] |
N = 5.6 M, R0 = 2.16–2.46 [98] N = 5.6 M, R0 = 2.58 [99] |
||
|
N = 145–570 M (1950–2100), R0 = 6 [9] N = 318–346 M (2010–2020), R0 = 6 [26] N = 158–478 M (1950–2100), R0 = 5 [33] N = 0.276 M (2013 Amish), R0 = 5 [41] N = 158–462 M (1950–2100), R0 = 5 [47] |
Houston, Louisiana [134] | N = 0.05–0.09 (deployed military personnel 2015–2025), R0 = V [163] R0 = V [158] |
|
Other countries modeled | ||||
|
N = 3.2 M (1996), R0 = 11 [10] N = 1.2–1.8 M (1950–2100), R0 = 11 [33] |
|||
|
N = 0.13 M (2012) [135] | |||
|
N = 5.9–7.0 M (1950–2100), R0 = 8 [33] | |||
|
N = 3.6 M (2000), R0 = 11 [10] | |||
|
N = 3.2–14.6 M (1950–2100), R0 = 9.5 [33] | |||
|
N = 74–254 M (1950–2100), R0 = 9 [33] | |||
|
N = 7 M (2015) [159] | |||
|
R0 = V [170] | |||
|
N = 15.2 M (1996), R0 = 5 [10] N = 10–17 M (1950–2100), R0 = 4 [33] N = 10–16 M (1950–2100), R0 = 5 [47] |
|||
|
N = 2.8 M, R0 = 1.5–1.85 [98] | |||
Theoretical or hypothetical populations | N = 100 M, R0 = 4–13 by WBIL [10] N = 10 or 100 M, R0 = 6–13 [14] N = 0.1 M, R0 = 13 [24] N = 0.1–1 M, R0 = 8–16 [27] N = 1 M, R0 = 10 [34, 69] N = 1 M, R0 = 3.6–11.7 [38, 39] N = 0.0035–0.01 M, R0 = 15,20,25 [70] |
N = 1 M, R0 = 3,10 [97] | R0 = V [147, 148, 151, 152, 156] N = 100%, R0 = 2.8 [149] N = 100%, R0 = 4–20 [154] N = 100%, R0 = 14 [160, 171] N = 100% (DEB), 0.001–0.1 M (IB), R0 = V [155] N = 100 M, R0 = 6 [150] N = 100 M, R0 = V [153] N = 0.2 M, R0 = 8–16 [161] N = 1 M, R0 = V [165] N = 0.0035–0.01 M, R0 = 15,20,25 [167–169] |
* See source for list of included countries.
Abbreviations: cVDPV(1,2,3), circulating vaccine-derived poliovirus(serotype 1, 2, or 3); DEB, differential-equation based; IB, individual-based; GPEI, Global Polio Eradication Initiative; IC, Imperial College; IDM, Institute for Disease Modeling; IPV, inactivated poliovirus vaccine; KRI, Kid Risk, Inc.; LI, low-income countries; LMI, lower middle-income countries; M, million; N, population; R0 basic reproduction number; UMI, upper middle-income countries; V = varied (used for R0 values, see paper); WBIL, World Bank Income Level; WPV(1,2,3), wild poliovirus(serotype 1, 2, or 3).